225 related articles for article (PubMed ID: 36056935)
41. CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.
Yang F; Zhang S; Meng Q; Zhou F; Pan B; Liu F; Yu Y
Pulm Pharmacol Ther; 2021 Apr; 67():102001. PubMed ID: 33582208
[TBL] [Abstract][Full Text] [Related]
42. Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis.
Deepak HB; Prince SE; Deshpande P
Indian J Pharmacol; 2022; 54(3):183-193. PubMed ID: 35848689
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
[TBL] [Abstract][Full Text] [Related]
44. Genetic analysis of cancer drivers reveals cohesin and CTCF as suppressors of PD-L1.
Oreskovic E; Wheeler EC; Mengwasser KE; Fujimura E; Martin TD; Tothova Z; Elledge SJ
Proc Natl Acad Sci U S A; 2022 Feb; 119(7):. PubMed ID: 35149558
[TBL] [Abstract][Full Text] [Related]
45. Differentially expressed JAK-STAT signaling pathway genes and target microRNAs in the spleen of necrotic enteritis-afflicted chicken lines.
Truong AD; Rengaraj D; Hong Y; Hoang CT; Hong YH; Lillehoj HS
Res Vet Sci; 2017 Dec; 115():235-243. PubMed ID: 28525837
[TBL] [Abstract][Full Text] [Related]
46. Cyclic adenosine monophosphate/phosphodiesterase 4 pathway associated with immune infiltration and PD-L1 expression in lung adenocarcinoma cells.
Tong L; Shan M; Zou W; Liu X; Felsher DW; Wang J
Front Oncol; 2022; 12():904969. PubMed ID: 35978822
[TBL] [Abstract][Full Text] [Related]
47. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
Yang X; Tang Z; Zhang P; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians.
Bie F; Tian H; Sun N; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhou B; Gao S
Clin Epigenetics; 2021 Dec; 13(1):229. PubMed ID: 34933667
[TBL] [Abstract][Full Text] [Related]
49. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
50. Analysis of JAK-STAT signaling pathway genes and their microRNAs in the intestinal mucosa of genetically disparate chicken lines induced with necrotic enteritis.
Truong AD; Rengaraj D; Hong Y; Hoang CT; Hong YH; Lillehoj HS
Vet Immunol Immunopathol; 2017 May; 187():1-9. PubMed ID: 28494922
[TBL] [Abstract][Full Text] [Related]
51. Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.
Tzeng HT; Chyuan IT; Lai JH
Biochem Pharmacol; 2021 Nov; 193():114760. PubMed ID: 34492272
[TBL] [Abstract][Full Text] [Related]
52. CircPRKCI regulates proliferation, migration and cycle of lung adenocarcinoma cells by targeting miR-219a-5p-regulated CAMK1D.
Sui MH; Zhang WW; Geng DM; Sun DJ
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(4):1899-1909. PubMed ID: 33660800
[TBL] [Abstract][Full Text] [Related]
53. Lowly expressed EGFR-AS1 promotes the progression of preeclampsia by inhibiting the EGFR-JAK/STAT signaling pathway.
Zhao ZM; Jiang J
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(19):6190-6197. PubMed ID: 30338781
[TBL] [Abstract][Full Text] [Related]
54. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Zhang N; Zeng Y; Du W; Zhu J; Shen D; Liu Z; Huang JA
Int J Oncol; 2016 Oct; 49(4):1360-8. PubMed ID: 27499357
[TBL] [Abstract][Full Text] [Related]
55. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells.
Kim J; Jang H; Lee GJ; Hur Y; Keum J; Jo JK; Yun SE; Park SJ; Park YJ; Choi MJ; Kim KS; Kim J
Cells; 2021 Dec; 11(1):. PubMed ID: 35011581
[TBL] [Abstract][Full Text] [Related]
56. Mechanism of hypoxia-induced exosome circ_0051799 regulating the progression of lung adenocarcinoma.
Zhu S; Liao B
Biol Chem; 2024 Feb; 405(2):143-160. PubMed ID: 37161917
[TBL] [Abstract][Full Text] [Related]
57. PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.
Jang HR; Shin SB; Kim CH; Won JY; Xu R; Kim DE; Yim H
Cell Death Differ; 2021 Sep; 28(9):2745-2764. PubMed ID: 33963314
[TBL] [Abstract][Full Text] [Related]
58. Immune infiltration landscape on prognosis and therapeutic response and relevant epigenetic and transcriptomic mechanisms in lung adenocarcinoma.
Zhang L; Jiang B; Lan Z; Yang C; Yao Y; Lin J; Wei Q
Front Immunol; 2022; 13():983570. PubMed ID: 36275753
[TBL] [Abstract][Full Text] [Related]
59. ACADL suppresses PD-L1 expression to prevent cancer immune evasion by targeting Hippo/YAP signaling in lung adenocarcinoma.
Li L; Wang LL; Wang TL; Zheng FM
Med Oncol; 2023 Mar; 40(4):118. PubMed ID: 36929466
[TBL] [Abstract][Full Text] [Related]
60. The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Guo CY; Zhu Q; Tou FF; Wen XM; Kuang YK; Hu H
BMC Cancer; 2019 Mar; 19(1):289. PubMed ID: 30925904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
